# Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)

> **NCT03056482** · PHASE4 · COMPLETED · sponsor: **Dr. Marco L.A. Sivilotti** · enrollment: 33 (actual)

## Conditions studied

- Cannabis Use Disorder

## Interventions

- **DRUG:** Ondansetron 8mg
- **DRUG:** Haloperidol 0.05mg/kg
- **DRUG:** Haloperidol 0.1mg/kg

## Key facts

- **NCT ID:** NCT03056482
- **Lead sponsor:** Dr. Marco L.A. Sivilotti
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-21
- **Primary completion:** 2019-06-30
- **Final completion:** 2019-07-07
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03056482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03056482, "Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03056482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*